(CLONEVO): Cell cycLe inhbitiON to Target the EVolution of UrOthelial Cancer
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Single-arm, open-label window-of-opportunity trial of neoadjuvant Abemaciclib in 20 patients,
with tumor tissue obtained as standard of care at tumor resection (pre-Abemaciclib) and
cystectomy (post-Abemaciclib)